New Two-Pronged immune cell therapy tested for tough lymphomas
NCT ID NCT05098613
Summary
This early-stage trial is testing the safety and best dose of a new type of CAR-T cell therapy. The therapy uses a patient's own modified immune cells to target two proteins (CD19 and CD22) on lymphoma cells. It is for adolescents and adults whose B-cell non-Hodgkin lymphoma has come back or hasn't responded to previous treatments, including other CAR-T therapies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Colorado Hospital
RECRUITINGAurora, Colorado, 80045, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.